Management meet Key Takeaways
Abbott India grew 5% in FY21 and 14% in Q4FY21. The company continues to outperform the IPM by 1.5x.
AIL management is confident on returning to historical double digit growth rate as IPM is showing signs of recovery at the start of FY22.
Enhancing access and awareness of focused and legacy brands to Tier II plus towns, exploring innovative channels to engage with the Doctors in these areas.
Digital platform to enable Doctors and patients one-stop solution patients support and counselling programs.
Duphaston occupying market leadership of 75% in dydrogesterone market.
The therapy was impacted amid pandemic due to postponement of appointments. AIL has invested in initiatives to address generic competition in Duphaston and have seen good traction with increasing acceptance by physicians. AIL expects some market share risk as few more competitors are expected to enter the segment.
Gastro Intestinal (GI) largest therapy in the AIL basket leading with three key brands like Creamaffin plus, Udiliv and Dufflac which continue to drive strong growth along with geographic expansion. Udiliv has grown 1.5x ahead of market and gained 3%ms despite generic competition and new players. Launch of Gutfit2.0 is expected to bring more growth to the segment.
Thyronorm continues to lead the segment and significant steps have been taken to enhance digital footprint of the brand which would aid the growth beyond pandemic.
Expansion to Tier II to Tier IV markets AIL confident of continuing the market beating growth.
OTC remains key strategic focus area for AIL meanwhile the segment largely comprises of antacid and laxative these would be further expanded by analgesics and preventive health. AIL expects to attain a sizable market share by FY25E.
E-pharmacy business has doubled in last one year do not forces any generic competition to hider this segment.
The Insulin share in sales mix has been similar to FY20. Top 3 and top 10 brand contribute 20% and 40% respectively and have grown ahead of participated markets. The field force stands at 2600 personnels with leading MRs productivity.
In FY21 the management has launched nearly 15+ products including brand extensions and expected to sustain the similar launch rate in FY22 as well. The key focus therapies for new launches would continue to be WH, Gastro, CNS, Vaccine and CH.